Bottom line
PHSYX vs HRTS: the short answer
PHSYX (Putnam Global Health Care Fund) and HRTS (Tema Heart & Health ETF) share a meaningful slice of their top holdings — about 62% by weight.
But PHSYX is far broader, holding 115 positions to 45 for HRTS, so beyond the top names it adds exposure HRTS doesn't have.
HRTS is cheaper at 0.75% vs 0.79% — a difference of $4.00 a year per $10,000 invested.
Over one year, HRTS returned +23.6% vs +1.5% for PHSYX (reporting dates differ).
Updated Nov 19, 2026
PHSYX vs HRTS side by side
| PHSYX | HRTS | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Franklin Templeton | Innovator |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.79% | 0.75% |
| Annual cost per $10k | $79 | $75 |
| 10-yr cost on $10k (prospectus) | $978 | $1,168 |
| Max front load | 0% | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +1.5% | +23.6% |
| 5-yr return (annualized) | +8.1% | — |
| 10-yr return (annualized) | +7.8% | — |
| Best quarter | — | +15.8% |
| Worst quarter | — | −12.4% |
| Net assets (fund) | $1.5B | $51.9M |
| Number of holdings | 115 | 45 |
| Portfolio turnover | 67% | 4% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
16 of PHSYX's top 25 holdings also appear in HRTS's top 25.
| Holding | PHSYX | HRTS |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 11.52% |
| Johnson & Johnson | 8.46% | 3.59% |
| UnitedHealth Group, Inc. | 6.93% | 5.24% |
| AbbVie, Inc. | 6.05% | 2.40% |
| Novartis AG | 5.13% | 3.38% |
| Merck & Co., Inc. | 4.88% | 4.27% |
| AstraZeneca plc | 4.67% | 4.00% |
| Thermo Fisher Scientific, Inc. | 4.50% | 3.97% |
| Edwards Lifesciences Corp. | 2.80% | 1.75% |
| Gilead Sciences, Inc. | 2.63% | 3.43% |
| McKesson Corp. | 2.14% | 1.71% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 2.93% |
| Novo Nordisk A/S | 1.90% | 5.24% |
| Bristol-Myers Squibb Co. | 1.75% | 2.09% |
| Dexcom, Inc. | 1.64% | 1.92% |
Source: SEC Form N-PORT
PHSYX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
HRTS top 10
- Eli Lilly & Co — 11.52%
- UnitedHealth Group Inc — 5.24%
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- AstraZeneca PLC — 4.00%
- Thermo Fisher Scientific Inc — 3.97%
- Johnson & Johnson — 3.59%
- Gilead Sciences Inc — 3.43%
- Novartis AG — 3.38%
FAQ
What is the difference between PHSYX and HRTS?
Which is cheaper, PHSYX or HRTS?
Should I own both PHSYX and HRTS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.